Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Open-Label, Randomized Controlled Trial of BL-M14D1 and Atezolizumab vs. Standard-of-Care Therapy in Patients With First-Line Extensive-Stage Small Cell Lung Cancer

NCT07625644 is registered in ClinicalTrials.gov with SystImmune Inc. as lead sponsor.

NCT NCT07625644
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07625644 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Open-Label, Randomized Controlled Trial of BL-M14D1 and Atezolizumab vs. Standard-of-Care Therapy in Patients With First-Line Extensive-Stage Small Cell Lung Cancer
Lead sponsor
SystImmune Inc.
Phase
Phase 3
Overall status
Recruiting
Start date
August 4, 2026
Completion date
June 30, 2031
Enrollment
550 (estimated)
Sites
62

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer, lung cancer metastatic, lung cancer stage iv, sclc, sclc,extensive stage, small cell carcinoma, small cell lung cancer extensive stage, small-cell lung cancer